Science Translational Medicine
Adenovirus-based vaccines can generate strong, broad, long-lasting, and functional T cell responses against hepatitis C virus (HCV) in healthy people, according to a study published in the Jan. 4 issue of .
Eleanor Barnes, M.D., of the University of Oxford in the United Kingdom, and colleagues used a recombinant adenoviral vector strategy in a phase 1 trial of an HCV vaccine in healthy human volunteers. Two adenoviral vectors expressing NS proteins from HCV genotype 1B were constructed based on rare serotypes (human adenovirus 6 and chimpanzee adenovirus 3).
The researchers found that both of the vectors primed T cell responses against HCV proteins.
Read more at: http://www.physiciansbriefing.com/Article.asp?AID=660393